Bevacizumab versus Dexamethasone Implant Followed by Bevacizumab for the Treatment of Macula Edema Associated with Branch Retinal Vein Occlusion
暂无分享,去创建一个
Yong-Kyu Kim | K. Cho | S. Woo | S. Moon | S. Park
[1] N. Eter,et al. Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study. , 2016, American journal of ophthalmology.
[2] Y. Mitamura,et al. Optical coherence tomography parameters predictive of visual outcome after anti-VEGF therapy for retinal vein occlusion , 2016, Clinical ophthalmology.
[3] J. Garweg,et al. Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex®) in its treatment , 2016, Graefe's Archive for Clinical and Experimental Ophthalmology.
[4] J. Chhablani,et al. In vivo evaluation of retinal ganglion cells degeneration in eyes with branch retinal vein occlusion , 2016, British Journal of Ophthalmology.
[5] P. Campochiaro,et al. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. , 2016, Ophthalmology.
[6] H. Lim,et al. Prediction of Retinal Ischemia in Branch Retinal Vein Occlusion: Spectral-Domain Optical Coherence Tomography Study. , 2015, Investigative ophthalmology & visual science.
[7] Ahmed S. Gado,et al. Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion‐related macular oedema: a prospective randomized comparison , 2014, Clinical & experimental ophthalmology.
[8] Min Kim,et al. Comparison of intravitreal bevacizumab and dexamethasone implant for the treatment of macula oedema associated with branch retinal vein occlusion , 2015, British Journal of Ophthalmology.
[9] P. Campochiaro,et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. , 2015, Ophthalmology.
[10] C. Chiquet,et al. Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naïve patients with retinal vein occlusion and macular edema: a 12-month follow-up study , 2015, Graefe's Archive for Clinical and Experimental Ophthalmology.
[11] Jae Hui Kim,et al. Short-term efficacy of intravitreal triamcinolone acetonide for macular edema secondary to retinal vein occlusion that is refractory to intravitreal bevacizumab , 2015, Indian journal of ophthalmology.
[12] Yong-Kyu Kim,et al. Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy , 2015, Graefe's Archive for Clinical and Experimental Ophthalmology.
[13] M. Gillies,et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. , 2014, Ophthalmology.
[14] G. Pertile,et al. Intravitreal Dexamethasone Implant for Macular Edema Secondary to Retinal Vein Occlusion: 12-month Follow-Up and Prognostic Factors , 2014, Ophthalmologica.
[15] Ahmed S. Gado,et al. Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion‐related macular oedema: a prospective randomized comparison , 2014, Clinical & experimental ophthalmology.
[16] D. Gaucher,et al. Prospective Pilot Study: Efficacy of Intravitreal Dexamethasone and Bevacizumab Injections in the Treatment of Macular Oedema Associated with Branch Retinal Vein Occlusion , 2013, Ophthalmologica.
[17] M. Blumenkranz,et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. , 2011, Ophthalmology.
[18] M. Figueroa,et al. Results of bevacizumab as the primary treatment for retinal vein occlusions , 2010, British Journal of Ophthalmology.
[19] P. Mitchell,et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. , 2010, Ophthalmology.
[20] Sarah Gray,et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.
[21] M. Blumenkranz,et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. , 2010, Ophthalmology.
[22] P. Campochiaro,et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.
[23] T. Meigen,et al. Comparison of Bevacizumab and Triamcinolone for Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion in a Pair-Matched Analysis , 2010, Ophthalmologica.
[24] Ingrid U Scott,et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. , 2009, Archives of ophthalmology.
[25] U. Schmidt-Erfurth,et al. Intravitreal bevacizumab (Avastin®) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial , 2008, British Journal of Ophthalmology.
[26] R. Avery,et al. INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION , 2007, Retina.
[27] J. Simpson,et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. , 2006, Ophthalmology.
[28] S. Hayreh. Prevalent misconceptions about acute retinal vascular occlusive disorders , 2005, Progress in Retinal and Eye Research.